14 April 2020
Advanced Medical Solutions Group plc
(“AMS”, the “Company” or the “Group”)
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, announces that it was notified on 8 April 2020 that on that same day, Derek Wright, husband of Penny Freer, a Non-Executive Director of the Company, purchased 2,112 ordinary shares of 5p each in the capital of the Company (“Ordinary Shares”) through his self-invested personal pension (“SIPP”) at a price of 247p per Ordinary Share.
Following the purchase, Mrs. Freer, together with her husband, have a total beneficial interest in the Company of 16,000 Ordinary Shares, representing approximately 0.0074% of the Company’s total voting rights.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
Details of the person discharging managerial responsibilities/person closely associated
Name: Derek Wright
Reason for the notification
Position/status: PCA with Non-Executive Director
Initial notification/Amendment: Initial Notification
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
Name: Advanced Medical Solutions Group plc
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Description of the financial instrument, type of instrument: Ordinary Shares of 5p each
Identification code: ISIN GB0004536594
Nature of the transaction:
· Purchase of 2,112 Ordinary Shares by a SIPP held in the name of Derek Wright, a person closely associated with Penny Freer
Price(s) and volume(s):
Aggregated volume: n/a
Aggregated price: n/a
Date of the transaction: 08/04/2020
Place of the transaction: London Stock Exchange, AIM Market (XLON)
For further information, please visit www.admedsol.com or contact:
Advanced Medical Solutions Group plc
Tel: 44 (0) 1606 545508
Chris Meredith, Chief Executive Officer
Eddie Johnson, Chief Financial Officer
Consilium Strategic Communications
Tel: 44 (0) 20 3709 5700
Mary-Jane Elliott / Matthew Neal / Olivia Manser
Investec Bank PLC (NOMAD & Broker)
Tel: 44 (0) 20 7597 5970
Daniel Adams / Gary Clarence / Patrick Robb
About Advanced Medical Solutions Group plc – see www.admedsol.com
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and woundcare markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, and internal fixation devices, which it markets under its brands LiquiBand®, RESORBA®, and LiquiBand® Fix8TM. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. In 2019, the Group made two acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; and Biomatlante, an established developer and manufacturer of innovative surgical biomaterial technologies based in France.
AMS’s products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France and Israel. Established in 1991, the Group has more than 700 employees. For more information, please see www.admedsol.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact email@example.com or visit www.rns.com.